Riociguat, sold under the brand name Adempas, is a medication used to treat two forms of pulmonary hypertension: pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). It works by relaxing the blood vessels in the lungs, which helps to reduce blood pressure and improve blood flow.
Riociguat is classified as a soluble guanylate cyclase (sGC) stimulator. It works by increasing the activity of sGC, an enzyme that helps to produce cyclic guanosine monophosphate (cGMP), a signaling molecule that helps to relax the smooth muscle in blood vessels.
Riociguat is taken orally, usually three times a day with or without food. The dose and duration of treatment may vary depending on the severity of the condition and the individual’s response to the medication. It is important to follow the dosing instructions provided by a healthcare provider.
Side effects of riociguat can include headache, dizziness, nausea, diarrhea, and low blood pressure. More serious side effects, such as bleeding or liver damage, are rare but can occur. Riociguat may also interact with certain medications, so it is important to inform a healthcare provider of all medications being taken.
Riociguat is generally considered safe and effective for the treatment of PAH and CTEPH, and has been approved for use in many countries worldwide. However, as with any medication, it is important to use riociguat only as directed and under the supervision of a qualified healthcare provider.